| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Marcel Levi | Q88497151 |
| P2860 | cites work | Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. | Q48020761 |
| Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. | Q51683065 | ||
| Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. | Q52846195 | ||
| Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. | Q53320452 | ||
| Dysfunction of Endothelial Protein C Activation in Severe Meningococcal Sepsis | Q57195132 | ||
| Efficacy and safety of recombinant human activated protein C for severe sepsis | Q29547839 | ||
| Thrombin signalling and protease-activated receptors | Q29619601 | ||
| Management of thrombotic thrombocytopenic purpura | Q33333063 | ||
| Time course of platelet counts in critically ill patients. | Q33341888 | ||
| Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis | Q33343555 | ||
| Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation | Q34303856 | ||
| Molecular basis for the relationship between thrombosis and cancer | Q34342948 | ||
| Pathogenetic mechanisms of thrombosis in malignancy | Q34363882 | ||
| Disseminated intravascular coagulation in trauma patients | Q34461301 | ||
| Disseminated intravascular coagulation in acute leukemia | Q34461307 | ||
| Regulatory role of cytokines in disseminated intravascular coagulation | Q34461332 | ||
| Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation | Q34461344 | ||
| Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial | Q34518326 | ||
| Regulation of inflammatory responses by natural anticoagulants | Q34579757 | ||
| Endothelium: interface between coagulation and inflammation | Q34633538 | ||
| New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins | Q34809827 | ||
| The diagnosis of disseminated intravascular coagulation. | Q34914193 | ||
| Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells | Q36851476 | ||
| Blood-borne tissue factor: another view of thrombosis | Q37181879 | ||
| Activation of Coagulation by Administration of Recombinant Factor VIIa Elicits Interleukin 6 (IL-6) and IL-8 Release in Healthy Human Subjects | Q39752330 | ||
| Diagnosis of disseminated intravascular coagulation. Role of D-dimer | Q41241326 | ||
| The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia | Q41354708 | ||
| Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca(++)-dependent complex of C-reactive protein with very-low-density lipoprotein and is a novel marker of impending disseminated intravascular coagulation. | Q44142838 | ||
| Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial | Q44506875 | ||
| Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. | Q47190616 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | disseminated intravascular coagulation | Q823027 |
| P304 | page(s) | 567-576 | |
| P577 | publication date | 2004-03-01 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | Current understanding of disseminated intravascular coagulation | |
| P478 | volume | 124 |
| Q36495558 | A Syrian golden hamster model recapitulating ebola hemorrhagic fever |
| Q93155975 | Animal Models of Inflammation for Screening of Anti-inflammatory Drugs: Implications for the Discovery and Development of Phytopharmaceuticals |
| Q36044569 | Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases |
| Q30421191 | Coinfection with Staphylococcus aureus increases risk of severe coagulopathy in critically ill children with influenza A (H1N1) virus infection. |
| Q84340569 | Current concepts in the management of disseminated intravascular coagulation |
| Q53662805 | Disseminated intravascular coagulation complicating acute lymphoblastic leukemia: a study of childhood and adult cases. |
| Q34623641 | Disseminated intravascular coagulation in a dog naturally infected by Leishmania (Leishmania) chagasi from Rio de Janeiro - Brazil |
| Q37730585 | Disseminated intravascular coagulation in malaria: A case report |
| Q42728168 | Disseminated intravascular coagulation or extended intravascular coagulation in massive pulmonary embolism |
| Q33612816 | Effect of cardiopulmonary bypass on activated partial thromboplastin time waveform analysis, serum procalcitonin and C-reactive protein concentrations |
| Q50864381 | Endothelial Cells. |
| Q48917097 | Evaluation of the Diagnostic Performance of Fibrin Monomer in Comparison to d-Dimer in Patients With Overt and Nonovert Disseminated Intravascular Coagulation |
| Q35971398 | Exotic emerging viral diseases: progress and challenges |
| Q48133922 | Extensive venous/lymphatic malformations causing life-threatening haematological complications |
| Q38762368 | Fatal haemolytic crisis with microvascular pulmonary obstruction mimicking a pulmonary embolism in a young African man with glucose-6-phosphate dehydrogenase deficiency. |
| Q44176213 | Fibrinogen level as a surrogate for the outcome of thrombolytic therapy using tissue plasminogen activator for acute lower extremity intravascular thrombosis |
| Q36759263 | Gaboon viper (Bitis gabonica) envenomation resulting from captive specimens--a review of five cases |
| Q37274431 | Hematological diseases and stroke |
| Q38615734 | Hemodialysis without Anticoagulation for a Patient with Chronic Disseminated Intravascular Coagulation |
| Q35300007 | Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus |
| Q59590875 | Hyperbaric oxygen therapy prevents coagulation disorders in an experimental model of multiple organ failure syndrome |
| Q98464576 | Immune Response and COVID-19: A mirror image of Sepsis |
| Q36759849 | Is there a microangiopathic antiphospholipid syndrome? |
| Q90904251 | Malignant meningioma mimicking chronic subdural hematoma |
| Q40602826 | Modulation of Interleukins in Sepsis-Associated Clotting Disorders: Interplay With Hemostatic Derangement |
| Q34325637 | Natural selection and the molecular basis of electrophoretic variation at the coagulation F13B locus |
| Q50459666 | Nimesulide-induced fatal acute liver failure in an elderly woman with metastatic biliary adenocarcinoma. A case report. |
| Q37334817 | Pulmonary embolism is more prevalent than deep vein thrombosis in cases of chronic obstructive pulmonary disease and interstitial lung diseases |
| Q25255548 | Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation. |
| Q34492729 | Recommendations for the transfusion management of patients in the peri-operative period. I. The pre-operative period |
| Q34988663 | Recommendations for the transfusion management of patients in the peri-operative period. II. The intra-operative period |
| Q35106170 | Recommendations for the transfusion management of patients in the peri-operative period. III. The post-operative period |
| Q37209117 | Recommendations for the transfusion of plasma and platelets |
| Q37559134 | Risk factors associated with provoked pulmonary embolism |
| Q34676688 | Role of tissue factor in thrombosis in antiphospholipid antibody syndrome |
| Q33370039 | Roles of protease-activated receptors in a mouse model of endotoxemia |
| Q42588928 | Sepsis-associated disseminated intravascular coagulation and thromboembolic disease |
| Q43357300 | Successful combined use of tranexamic acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis. |
| Q37909137 | Systemic versus localized coagulation activation contributing to organ failure in critically ill patients |
| Q36156027 | The anticoagulant protein C pathway |
| Q41344164 | The coagulopathy in sepsis: significance and implications for treatment |
| Q33677056 | The effect of hemostatic dressing prototypes for the uniformed services on selected blood coagulation parameters in pigs. |
| Q36198065 | The efficacy of recombinant human soluble thrombomodulin for obstetric disseminated intravascular coagulation: a retrospective study |
| Q37952402 | The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia |
| Q36053839 | The role of plasmapheresis in critical illness |
| Q33399094 | Thrombocytopenia in the intensive care unit |
Search more.